Oral administration of a PPAR-δ agonist to rodents worsens, not improves, maximal insulin-stimulated glucose transport in skeletal muscle of different fibers

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 299, Issue 2, 2010, Pages

  Cresser, Justin ^a   Bonen, Arend ^a   Chabowski, Adrian ^b   Stefanyk, Leslie E ^a   Gulli, Roberto ^a   Ritchie, Ian ^a   Dyck, David J ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Ceramide; Diacylglycerol; Fatty acid transport; High fat diet; Insulin resistance; Oxidative capacity

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; CD36 ANTIGEN; CERAMIDE; DIACYLGLYCEROL; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; P85 PHOSPHOINOSITIDE 3 KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; SATURATED FATTY ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EPITROCHLEARIS MUSCLE; FATTY ACID BLOOD LEVEL; FEMALE; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCOLYSIS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; MUSCLE CELL; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; SARCOLEMMA; SOLEUS MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD36; BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; CERAMIDES; DIETARY FATS; DIGLYCERIDES; FATTY ACID-BINDING PROTEINS; FEMALE; GLUCOSE TRANSPORTER TYPE 4; GLYCOLYSIS; GTPASE-ACTIVATING PROTEINS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MUSCLE FIBERS, SKELETAL; OXIDATION-REDUCTION; PHOSPHORYLATION; PPAR DELTA; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES;

EID: 77955477569     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00431.2009     Document Type: Article

References (53)

1. Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med 262: 184-198, 2007.
2. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590-597, 2006.
3. Bonen A, Parolin ML, Steinberg GR, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ, Heigenhauser GJ, Dyck DJ. Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36. FASEB J 18: 1144-1146, 2004.
4. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354-366, 1996.
5. Bruce CR, Thrush AB, Mertz VA, Bezaire V, Chabowski A, Heigenhauser GJ, Dyck DJ. Endurance training in obese humans improves glucose tolerance and mitochondrial fatty acid oxidation and alters muscle lipid content. Am J Physiol Endocrinol Metab 291: E99-E107, 2006.
6. Brunmair B, Staniek K, Dorig J, Szocs Z, Stadlbauer K, Marian V, Gras F, Anderwald C, Nohl H, Waldhausl W, Furnsinn C. Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids. Diabetologia 49: 2713-2722, 2006.
7. Chabowski A, Chatham JC, Tandon NN, Calles-Escandon J, Glatz JF, Luiken JJ, Bonen A. Fatty acid transport and FAT/CD36 are increased in red but not in white skeletal muscle of ZDF rats. Am J Physiol Endocrinol Metab 291: E675-E682, 2006.
8. Chabowski A, Gorski J, Bonen A. Regulation of fatty acid transport: from transcriptional to posttranscriptional effects. Naunyn Schmiedebergs Arch Pharmacol 373: 259-263, 2006.
9. Chen MT, Kaufman LN, Spennetta T, Shrago E. Effects of high fat-feeding to rats on the interrelationship of body weight, plasma insulin, and fatty acyl-coenzyme A esters in liver and skeletal muscle. Metabolism 41: 564-569, 1992.
10. Constantin D, Constantin-Teodosiu D, Layfield R, Tsintzas K, Bennett AJ, Greenhaff PL. PPARdelta agonism induces a change in fuel metabolism and activation of an atrophy programme, but does not impair mitochondrial function in rat skeletal muscle. J Physiol 583: 381-390, 2007.
11. Constantin-Teodosiu D, Baker DJ, Constantin D, Greenhaff PL. PPARdelta agonism inhibits skeletal muscle PDC activity, mitochondrial ATP production and force generation during prolonged contraction. J Physiol 587: 231-239, 2009.
12. Debard C, Cozzone D, Ricard N, Vouillarmet J, Disse E, Husson B, Laville M, Vidal H. Short-term activation of peroxysome proliferator-activated receptor beta/delta increases fatty acid oxidation but does not restore insulin action in muscle cells from type 2 diabetic patients. J Mol Med 84: 747-752, 2006.
13. Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, Staels B. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett 471: 34-38, 2000.
14. Dimopoulos N, Watson M, Green C, Hundal HS. The PPARdelta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells. FEBS Lett 581: 4743-4748, 2007.
15. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 17: 2477-2493, 2003.
16. Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW, Cooney GJ. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab 279: E554-E560, 2000.
17. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl 1: S43-S50, 2004.
18. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509, 1957.
19. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferatoractivated receptors alpha and delta. Proc Natl Acad Sci USA 94: 4312-4317, 1997.
20. He J, Kelley DE. Muscle glycogen content in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 287: E1002-E1007, 2004.
21. Herr HJ, Bernard JR, Reeder DW, Rivas DA, Limon JJ, Yaspelkis BB, 3rd. Insulin-stimulated plasma membrane association and activation of Akt2, aPKC zeta and aPKC lambda in high fat fed rodent skeletal muscle. J Physiol 565: 627-636, 2005.
22. Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, Abumrad NA. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem 274: 26761-26766, 1999.
23. Jucker BM, Yang D, Casey WM, Olzinski AR, Williams C, Lenhard SC, Legos JJ, Hawk CT, Sarkar SK, Newsholme SJ. Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study. Am J Physiol Endocrinol Metab 293: E1256-E1264, 2007.
24. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355-7359, 1994.
25. Koshinaka K, Oshida Y, Han YQ, Kubota M, Viana AY, Nagasaki M, Sato Y. Insulin-nonspecific reduction in skeletal muscle glucose transport in high-fat-fed rats. Metabolism 53: 912-917, 2004.
26. Kramer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 282: 19313-19320, 2007.
27. Kramer DK, Al-Khalili L, Perrini S, Skogsberg J, Wretenberg P, Kannisto K, Wallberg-Henriksson H, Ehrenborg E, Zierath JR, Krook A. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta. Diabetes 54: 1157-1163, 2005.
28. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103: 3444-3449, 2006.
29. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi PA. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 17: 2299-2301, 2003.
30. Mullen KL, Smith AC, Junkin KA, Dyck DJ. Globular adiponectin resistance develops independently of impaired insulin-stimulated glucose transport in soleus muscle from high-fat-fed rats. Am J Physiol Endocrinol Metab 293: E83-E90, 2007.
31. Nickerson JG, Alkhateeb H, Benton CR, Lally J, Nickerson J, Glatz JFC, Chabowski A, Luiken JJFP, Bonen A. Greater transport efficiencies of the membrane fatty acid transporters and FAT/CD36 and FATP4 compared with FABPpm and FATP1 and diffential effects on fatty acid esterification and oxidation in rat skeletal muscle. J Biol Chem 284: 16522-16530, 2009.
32. Oliver WR Jr., Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98: 5306-5311, 2001.
33. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 272: 27307-27312, 1997.
34. Riserus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57: 332-339, 2008.
35. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, Auwerx J. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 270: 19269-19276, 1995.
36. Singh MK, Krisan AD, Crain AM, Collins DE, Yaspelkis BB, 3rd. High-fat diet and leptin treatment alter skeletal muscle insulin-stimulated phosphatidylinositol 3-kinase activity and glucose transport. Metabolism 52: 1196-1205, 2003.
37. Smith AC, Mullen KL, Junkin KA, Nickerson J, Chabowski A, Bonen A, Dyck DJ. Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia. Am J Physiol Endocrinol Metab 293: E172-E181, 2007.
38. Song XM, Kawano Y, Krook A, Ryder JW, Efendic S, Roth RA, Wallberg-Henriksson H, Zierath JR. Muscle fiber type-specific defects in insulin signal transduction to glucose transport in diabetic GK rats. Diabetes 48: 664-670, 1999.
39. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514, 1998.
40. Srere PA. Citrate synthase. Methods Enzymol 13: 3-11, 1969.
41. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 45: 42-72, 2006.
42. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR Jr. Sternbach DD. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta) - synthesis and biological activity. Bioorg Med Chem Lett 13: 1517-1521, 2003.
43. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100: 15924-15929, 2003.
44. Terada S, Wicke S, Holloszy JO, Han DH. PPARdelta activator GW- 501516 has no acute effect on glucose transport in skeletal muscle. Am J Physiol Endocrinol Metab 290: E607-E611, 2006.
45. Timmers S, Schrauwen P, de Vogel J. Muscular diacylglycerol metabolism and insulin resistance. Physiol Behav 94: 242-251, 2008.
46. Tremblay F, Lavigne C, Jacques H, Marette A. Defective insulininduced GLUT4 translocation in skeletal muscle of high fat-fed rats is associated with alterations in both Akt/protein kinase B and atypical protein kinase C (zeta/lambda) activities. Diabetes 50: 1901-1910, 2001.
47. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5= flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11: 433-439, 1992.
48. Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, Macphee CH, Pinto I, Smith SA, Suckling KE, Wolf CR, Palmer CN. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 276: 44258-44265, 2001.
49. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113: 159-170, 2003.
50. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2: e294, 2004.
51. Wilkes JJ, Bonen A, Bell RC. A modified high-fat diet induces insulin resistance in rat skeletal muscle but not adipocytes. Am J Physiol Endocrinol Metab 275: E679-E686, 1998.
52. Willson TM, Wahli W. Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1: 235-241, 1997.
53. Zierath JR, Houseknecht KL, Gnudi L, Kahn BB. High-fat feeding impairs insulin-stimulated GLUT4 recruitment via an early insulin-signaling defect. Diabetes 46: 215-223, 1997.